An Australian expert has rejected claims that oncology clinical trials are increasingly compromised by use of surrogate outcomes and industry funding. A new review has noted a swing in recent years to greater use of surrogate end points along with a “massive shift” to pharmaceutical industry sponsorship. The study of trends in randomised controlled trials ...
Australian expert rejects criticism of oncology trials bias
By Julie Lambert
13 Apr 2021